Advancements in Insulin Delivery Poised to Revolutionise Diabetes Management

    LONDON, August 8 /PRNewswire/ -- Innovative, non-invasive methods to
 deliver insulin are poised to transform diabetes management. Despite
 concerns about their safety and efficacy, an eager diabetic community is
 expected to support research into novel technologies that promote greater
 compliance and therefore improved disease management. Accordingly, the
 revenue potential across Europe of non-invasive insulin, particularly
 inhaled insulin, will be considerable.
     Frost & Sullivan (http://www.pharma.frost.com) finds that the European
 Inhaled Insulin Market will earn revenues of US$49.3 million in 2006 and
 estimates this to reach US$611.7 million in 2012.
     "Compliance is currently a major drawback in current diabetes delivery
 devices, with several patients suffering from Type 2 diabetes irregularly
 following or, in some cases, even discontinuing their insulin therapy due
 to pain or fear of injections," says Frost & Sullivan Research Analyst
 Sylvia Miriyam Findlay. "Through more convenient drug delivery methods,
 pharmaceutical companies, regulatory bodies and other government
 institutions can introduce better diabetes care and reduce costs related to
 diabetic complications caused by poor compliance."
     At present, several methods of non-invasive insulin delivery, including
 oral, transdermal, nanotechnology-based and gene therapy-based ones, are
 under research. Efforts are also on to develop a diabetes vaccine. One of
 the most promising modes of delivery under investigation is that of inhaled
 insulin.
     Leading participants in the diabetes medication market are vying to
 develop this new form of insulin delivery. Already, Exubera (Pfizer and
 Netkar) has become the first inhaled insulin to enter the market, while
 Novo Nordisk is pursuing final clinical studies on AerX with plans to
 launch it by 2008.
     However, the inhaled insulin market faces concerns over the long-term
 safety and efficacy of using the pulmonary insulin delivery method.
 Occurrences of pulmonary fibrosis during clinical trials and the incidence
 of side effects are restraining the uptake of inhaled insulin.
     In addition, due to high production costs, inhaled insulins are likely
 to be priced three to five times higher than conventional ones. This price
 premium will challenge manufacturers, although the price factor will be
 balanced out by its greater convenience.
     "As the European markets are driven by the convenience factor,
 companies will need to analyse dosing accuracy, bioavailability and the
 device size," says Ms. Findlay. "This novel drug delivery method will have
 to demonstrate its advantages in terms of safety and accuracy relative to
 current insulin injections."
     The ability to prove its safety and convenience will determine the
 uptake of the inhaled insulin method. Manufacturers of inhaled insulin
 devices will need to focus on the long-term safety and convenience aspects
 of their products, with the incorporation of newer techniques in inhaler
 devices set to enhance convenience.
     If you are interested in a virtual brochure, which provides
 manufacturers, end users, and other industry participants with an overview
 of the latest analysis of the Diabetes Drug Delivery Methods-Market and
 Technologies (B934-52) then send an e-mail to Radhika Menon Theodore-
 Corporate Communications at rmtheodore@frost.com with the following
 information: your full name, company name, title, telephone number, e-mail
 address, city, state, and country. We will send you the information via
 email upon receipt of the above information.
     Diabetes Drug Delivery Methods-Market and Technologies is part of the
 Pharmacueticals/Biotechology Subscription, which also includes research in
 the following markets: European Diabetes Market, European CNS Market
 Analysis, European Alzheimer's Market, European Cancer Market. All research
 included in subscriptions provide detailed market opportunities and
 industry trends that have been evaluated following extensive interviews
 with market participants. Interviews are available to the press.
     Frost & Sullivan, a global growth consulting company, has been
 partnering with clients to support the development of innovative strategies
 for more than 40 years. The company's industry expertise integrates growth
 consulting, growth partnership services and corporate management training
 to identify and develop opportunities. Frost & Sullivan serves an extensive
 clientele that includes Global 1000 companies, emerging companies and the
 investment community by providing comprehensive industry coverage that
 reflects a unique global perspective and combines ongoing analysis of
 markets, technologies, econometrics and demographics. For more information,
 visit www.frost.com.
     Diabetes Drug Delivery Methods-Market and Technologies
     B934-52
     Keywords in this release: diabetes, drug delivery methods, diabetes
 drug delivery market, diabetes drug delivery methods, diabetes drug
 delivery technologies, non-invasive drug delivery, insulin, Europe,
 diabetes management, diabetes medication, diabetic, non-invasive insulin,
 inhaled insulin, diabetes delivery devices, Type 2 diabetes, insulin
 therapy, diabetics care, diabetic complications, oral insulin delivery,
 transdermal insulin delivery, nanotechnology-based insulin delivery, gene
 therapy-based insulin delivery, diabetes vaccine, Exubera, Pfizer, Netkar
 Novo Nordisk, AerX, pulmonary insulin delivery, pulmonary fibrosis,
 bioavailability
     Contact:
     Radhika Menon Theodore
     Corporate Communications - Europe
     P: +91-44-42044541
     F: +91-44-24314264
     E: rmtheodore@frost.com
 
     Melina Trevino
     Corporate Communications - Americas
     P: +1-210-247-2440
     F: +1-210-348-1003
     E: melina.trevino@frost.com
 
     Surbhi Dedhia
     Corporate Communications - India
     P: +91-22-5001-3431
     E: sdedhia@frost.com
 
     Jasminder Kaur
     Corporate Communications - Asia Pacific
     P: +65-68900937
     E: jkaur@frost.com
 
     Sharmin Jassal
     Corporate Communications - Australia
     P: +61-2-8247-8900
     F: +61-2-9252-8066
     E: sjassal@frost.com
 
 
     www.frost.com
 
 

SOURCE Frost & Sullivan
RELATED LINKS
http://www.frost.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.